Dammacco 2001.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 145, multiple myeloma; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = 12‐14 g/dL planned ESA duration = 12 weeks
Outcomes	Primary: transfusion; secondary: Hb, Hct, reticulocytes, serum erythropoietin levels, QoL
Notes	study number = 11220
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	randomization schedule prepared by RWJPRI
Allocation concealment?	Unclear risk	two randomization lists (patients previously transfused or not), when patient enters the study the next number was to be assigned